CMAJ • October 12, 2004; 171 (8). doi:10.1503/cmaj.1031789.
© 2004 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow [Online Tables]
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hsiung, G.-Y. R.
Right arrow Articles by Feldman, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hsiung, G.-Y. R.
Right arrow Articles by Feldman, H.
Related Collections
Right arrow Dementia
Right arrowRelated Article

Research
Recherche

Apolipoprotein E {epsilon}4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging

Ging-Yuek R. Hsiung, A. Dessa Sadovnick and Howard Feldman

From the Department of Medicine, Clinic for Alzheimer's Disease and Related Disorders (Hsiung, Feldman), and the Department of Medical Genetics (Hsiung, Sadovnick), University of British Columbia, Vancouver, BC

Background: Apolipoprotein E (ApoE) {epsilon}4 genotype is a well-established risk factor for Alzheimer's disease (AD). However, its effect on predicting conversion from normal to "cognitive impairment, no dementia" (CIND) and from CIND to AD is less clear.

Methods: We used a nested case–control design from the population-based Canadian Study of Health and Aging (CSHA) to examine the effect of ApoE {epsilon}4 genotype on the conversion of subjects from normal to CIND and from CIND to AD. We also contrasted these findings with incident cases of AD and vascular dementia (VaD) in the CSHA cohort.

Results: The ApoE {epsilon}4 genotype was a significant risk factor for conversion from CIND to AD and from normal to AD and VaD. However, it was not a significant risk factor for conversion from normal to CIND. This effect is robust to adjustment for age, sex and education level. There is significant interaction between the ApoE {epsilon}4 genotype and age for AD and for conversion from CIND to AD. No interaction between ApoE {epsilon}4 genotype, sex, age, ethnicity and education level was found in other subgroup analyses. The positive predictive value of ApoE {epsilon}4 for predicting CIND conversion to AD was 0.48, and the negative predictive value was 0.65.

Interpretation: Possession of an ApoE {epsilon}4 allele increases the risk of AD developing from CIND. It is also associated with a decrease in the age at onset of AD. Its predictive values do not support its utility as a diagnostic test for predicting progression from CIND to AD, but it may be useful in research studies to enrich study samples that have a higher rate of progression to AD.


Related Article

The benefits of apolipoprotein E {epsilon}4 screening to research
Serge Gauthier
Can. Med. Assoc. J. 2004 171: 881. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
B. S. Silbert, L. A. Evered, D. A. Scott, and T. F. Cowie
The Apolipoprotein E {epsilon}4 Allele is not Associated With Cognitive Dysfunction in Cardiac Surgery
Ann. Thorac. Surg., September 1, 2008; 86(3): 841 - 847.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
Y. P. Jin, T. Ostbye, J. W. Feightner, S. Di Legge, and V. Hachinski
Joint effect of stroke and APOE 4 on dementia risk: The Canadian Study of Health and Aging
Neurology, January 1, 2008; 70(1): 9 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
S. L. Tyas, J. C. Salazar, D. A. Snowdon, M. F. Desrosiers, K. P. Riley, M. S. Mendiondo, and R. J. Kryscio
Transitions to Mild Cognitive Impairments, Dementia, and Death: Findings from the Nun Study
Am. J. Epidemiol., June 1, 2007; 165(11): 1231 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. T. Tschanz, K. A. Welsh-Bohmer, C. G. Lyketsos, C. Corcoran, R. C. Green, K. Hayden, M. C. Norton, P. P. Zandi, L. Toone, N. A. West, et al.
Conversion to dementia from mild cognitive disorder: the Cache County Study.
Neurology, July 25, 2006; 67(2): 229 - 234.
[Abstract] [Full Text] [PDF]

Home page
 J Geriatr Psychiatry NeurolHome page
G. E. Swan, C. N. Lessov-Schlaggar, D. Carmelli, G. D. Schellenberg, and A. La Rue
Apolipoprotein E {epsilon}4 and Change in Cognitive Functioning in Community-Dwelling Older Adults
J Geriatr Psychiatry Neurol, December 1, 2005; 18(4): 196 - 201.
[Abstract] [PDF]

Home page
 ChestHome page
L. Gao, R. Taha, D. Gauvin, L. B. Othmen, Y. Wang, and G. Blaise
Postoperative Cognitive Dysfunction After Cardiac Surgery
Chest, November 1, 2005; 128(5): 3664 - 3670.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
W. S. Rubinstein and H. K. Roy
Practicing Medicine at the Front Lines of the Genomic Revolution
Arch Intern Med, September 12, 2005; 165(16): 1815 - 1817.
[Full Text] [PDF]

Home page
 CMAJHome page
S. Gauthier
The benefits of apolipoprotein E {epsilon}4 screening to research
Can. Med. Assoc. J., October 12, 2004; 171(8): 881 - 881.
[Full Text] [PDF]